(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 157.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.02%.
Cibus's revenue in 2026 is $3,639,000.On average, 6 Wall Street analysts forecast CBUS's revenue for 2026 to be $569,068,907, with the lowest CBUS revenue forecast at $425,971,327, and the highest CBUS revenue forecast at $726,559,281. On average, 5 Wall Street analysts forecast CBUS's revenue for 2027 to be $1,195,086,223, with the lowest CBUS revenue forecast at $911,520,515, and the highest CBUS revenue forecast at $1,483,841,640.
In 2028, CBUS is forecast to generate $5,167,012,822 in revenue, with the lowest revenue forecast at $4,964,406,577 and the highest revenue forecast at $5,318,967,506.